Comorbidity Remission Following Intragastric Dual Balloon Placement
The intragastric dual balloon was FDA approved in 2015 for the treatment of obesity. The objective of this study was to report the weight loss, comorbidity remission, and biochemical improvements experienced by 28 patients following intragastric dual balloon placement at a single institution between September 2015 and June 2017. Demographic data were collected preoperatively. Anthropometric, clinical, and biochemical data were collected preoperatively and 3 and 6 months postoperatively. Two patients were lost to data follow-up. Participants experienced significant improvements in blood pressure and lipid profiles, in addition to substantial weight loss 6 months after balloon insertion. The results of this study underscore the promise of the intragastric dual balloon as an efficacious intervention for weight loss and comorbidity remission in patients with early-stage obesity.
KeywordsIntragastric balloons ReShape Bariatric surgery Weight loss Obesity
Compliance with Ethical Standards
This study was approved by the appropriate university institutional review board, and participants completed written, informed consent.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 4.Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity among adults and youth: United States, 2015-2016. NCHS Data Brief. 2017;288:1–8.Google Scholar
- 9.Daniel S, Soleymani T, Garvey WT. A complications-based clinical staging of obesity to guide treatment modality and intensity. Curr Opin Endocrinol Diabetes Obes. 2013;20(5):377–88. https://doi.org/10.1097/01.med.0000433067.01671.f5.CrossRefGoogle Scholar